Browse the evidence

Injectable semaglutide 2.4 mg once weekly produces significant weight loss (mean 15.2% over 104 weeks) and improves cardiometabolic risk factors in adults with obesity.

If you have obesity and struggle to lose weight through diet and exercise alone, ask your doctor about injectable semaglutide (2.4 mg once weekly). It is clinically proven to help you lose an average of 15% of your body weight over two years and improves heart health markers. Be prepared for a slow start to minimize stomach upset, and stick with it as the benefits are significant.

Intermittent Fasting (IMF) produces weight loss equivalent to Daily Caloric Restriction (DCR) when both interventions are delivered with comprehensive behavioral support and equal energy deficits, though IMF may offer better long-term fat mass maintenance.

This paper does not provide results, only a plan. However, it suggests that for weight loss, the specific timing of eating (fasting vs. daily restriction) matters less than sticking to the plan. If you struggle with daily calorie counting, trying fasting might work, but you need strong behavioral support (coaching, tracking) to succeed, just as you would with daily restriction.

Participation in exercise-based cardiac rehabilitation (CR) for patients with coronary heart disease significantly reduces cardiovascular mortality, recurrent myocardial infarction, and hospitalizations compared to no-exercise control, while also improving health-related quality of life.

If you have coronary heart disease, participating in a structured exercise-based cardiac rehabilitation program is one of the most effective steps you can take to lower your risk of dying from heart causes, having another heart attack, or being hospitalized. You do not need to be an elite athlete; programs vary in intensity and setting (home or center), but the key is consistent, supervised physical activity combined with education. This is recommended alongside modern medical treatments, not instead of them.

Exercise programs (strength, aerobic, flexibility, or neuromotor) of adequate dosage with progression tailored to physical function improve pain and function in hip and knee osteoarthritis.

Start an exercise program tailored to your current ability. It can include strength, aerobic, flexibility, or neuromotor exercises. Progress gradually. Exercise is safe and effective for reducing pain and improving function in osteoarthritis.

Administering tirzepatide (10 or 15 mg once weekly) to adults with overweight or obesity who have already achieved ≥5% weight loss through intensive lifestyle intervention results in substantial additional weight reduction (mean -18.4% from randomization) and prevents weight regain compared to placebo.

If you have successfully lost at least 5% of your body weight through diet and exercise, adding once-weekly tirzepatide (10 or 15 mg) can help you lose an additional ~18% of your body weight and prevent the typical weight regain seen after lifestyle interventions. This approach is particularly relevant if you have obesity-related complications, as it offers superior cardiometabolic benefits compared to lifestyle changes alone.

Semaglutide 2.4 mg improves anthropometric measures (waist circumference, waist-to-height ratio, BMI category) and reduces serious adverse events in patients with obesity and cardiovascular disease, regardless of baseline BMI category.

Semaglutide 2.4 mg not only reduces overall weight but also specifically targets visceral fat (waist circumference) and improves waist-to-height ratio, which are key markers for cardiovascular risk. These benefits, along with a reduced rate of serious adverse events, are consistent across all obesity classes, including those with a BMI just over 30.

Implementing a structured, EHR-driven care process (PATHWEIGH) in primary care mitigates population-level weight gain and increases the likelihood of patients receiving weight-related care, even among those who do not receive direct clinical intervention.

If you are a healthcare system, stop waiting for patients to ask for help. Use your electronic health records to flag patients with high BMI and prompt doctors to discuss weight. Educate your staff that obesity is a chronic disease, not a lifestyle failure. This simple process change can help patients lose weight even if they never see a specialist.

In individuals with type 2 diabetes, a carbohydrate-reduced high-protein (CRHP) diet (30E% carbs, 30E% protein, 40E% fat) induces greater improvements in glycaemic control (HbA1c, diurnal glucose) and reduces liver fat compared to a conventional diabetes diet (50E% carbs, 17E% protein, 33E% fat), even when both diets produce matched weight loss.

For a person with Type 2 Diabetes, switching to a diet with 30% of calories from carbs, 30% from protein, and 40% from fat (while maintaining a calorie deficit to lose weight) can improve blood sugar control and reduce liver fat more effectively than a standard high-carb diabetes diet, even if both diets result in the same amount of weight loss. However, be aware that this diet may not reduce fat stored in the pancreas as much as a standard diet.

Long-acting GLP-1 receptor agonists significantly reduce glycated hemoglobin (HbA1c) levels and body weight in adults, with greater efficacy observed in patients with type 2 diabetes compared to non-diabetic overweight individuals.

Long-acting GLP-1 receptor agonists (like semaglutide or liraglutide) are effective for lowering blood sugar and reducing body weight in adults. The effect is more pronounced in people with type 2 diabetes. Common side effects include gastrointestinal issues, which may vary by individual. Consult a healthcare provider to determine if these medications are appropriate for your specific health profile.

There is a negative correlation between glycemic control (HbA1c reduction) and body weight reduction at the between-study level in all participants, but a positive correlation exists when analyzing patients with diabetes or non-diabetic participants separately.

For people with diabetes, GLP-1 RAs tend to improve both blood sugar and weight loss together. For non-diabetic individuals, these drugs still cause weight loss, but this may not translate to improved blood sugar markers since their levels are already normal. The relationship between weight loss and glycemic control is complex and depends on your starting health status.

GLP-1 receptor agonists (semaglutide, tirzepatide) and bariatric surgery produce substantial weight loss (>10-15%) and improve cardiometabolic risk factors, but weight regain is common upon discontinuation, often necessitating lifelong treatment.

GLP-1 medications and surgery are currently the most effective tools for significant weight loss and metabolic improvement. However, they are not 'cures'; stopping them typically leads to weight regain. If you choose this path, prepare for it to be a long-term or lifelong commitment, and verify insurance coverage or affordability before starting.

Testosterone therapy in older men with low testosterone and symptoms improves sexual function, anemia, and bone mineral density, and prevents type 2 diabetes in high-risk men, while demonstrating cardiovascular safety in large RCTs.

If you are an older man with low testosterone and symptoms, testosterone therapy can improve sexual function, blood counts, and bone density. For those at high risk of diabetes, it significantly reduces that risk. Large recent studies confirm it is safe for the heart and prostate, so discuss this with your doctor if you meet the criteria.

Weekly subcutaneous semaglutide (titrated to 2.0 mg) significantly reduces body weight in clozapine-treated patients with schizophrenia and obesity compared to placebo over 36 weeks.

This protocol outlines a clinical trial for using semaglutide to treat obesity in people with schizophrenia taking clozapine. It is not a general recommendation but a research study. If you are interested, consult your psychiatrist about eligibility for clinical trials, as this specific intervention is currently under investigation for this population.

A phone-based intervention using Motivational Interviewing (MI) principles delivered by a trained nurse significantly improves adherence to Continuous Positive Airway Pressure (CPAP) therapy in patients with Obstructive Sleep Apnea Syndrome (OSAS) compared to usual care alone.

If you have sleep apnea and are struggling to use your CPAP machine, standard instructions might not be enough. This study suggests that talking with a nurse who uses Motivational Interviewing techniques—focusing on your reasons for wanting to get better and building your confidence—can help you stick with the therapy longer. The key is personalized support: if you are struggling early on, you get more frequent check-ins to help you overcome barriers.

Obesity pharmacotherapy reduces the risk of major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease (ASCVD) and BMI ≥ 27, independent of diabetes status.

If you have heart disease and are overweight (BMI ≥ 27), ask your doctor about semaglutide (Wegovy). It has been proven to reduce the risk of heart attacks and strokes, in addition to helping with weight loss.

Pharmacological treatment for obesity is indicated for adults with a BMI ≥30 kg/m², or ≥27 kg/m² with at least one comorbidity, when lifestyle changes are insufficient to achieve or maintain weight loss objectives.

If your BMI is 30 or higher, or 27 or higher with a health condition like diabetes or high blood pressure, and diet and exercise haven't worked, you qualify for prescription weight-loss medication. This is a standard medical indication, not a failure of willpower. Discuss this with your doctor to see if it's appropriate for you.

Anti-obesity medications should be used as part of a multidisciplinary approach that includes lifestyle changes, behavioral management, and long-term follow-up, rather than as a standalone solution.

Medication is a tool, not a cure. It works best when combined with healthy eating, physical activity, and behavioral support. Your doctor will likely recommend a multidisciplinary approach to ensure long-term success.

An intensive 6-month cardiac rehabilitation program combining a moderate-carbohydrate Mediterranean diet, exercise training, and time-restricted eating (8:16) can reverse pre-diabetes to normal glucose concentrations in patients with coronary heart disease.

If you have heart disease and pre-diabetes, a structured 6-month program can help reverse your blood sugar levels. Start with a Mediterranean-style diet (less than 40% carbs, mostly plants/fish/olive oil) and reduce ultra-processed foods. Add supervised exercise (mix of steady cardio and high-intensity intervals plus strength training) 3 times a week. After 3 months, add an 8-hour eating window (16 hours fasting) 5 days a week. Do this under medical supervision.

Integrating dietary quality improvements with behavioral strategies focused on everyday-life agency and self-management capacity yields stronger effects on glucose control and dietary quality than standard counseling or single-modality interventions.

To manage Type 2 Diabetes effectively, move beyond just counting carbs or calories. Focus on building your ability to manage your health within your actual daily life and social situations. This involves active learning and developing 'agency' over your eating habits, supported by regular check-ins with healthcare providers, rather than just receiving static dietary advice.

Semaglutide 2.4 mg/week administered as an add-on to hospital-based non-pharmacological obesity care significantly reduces adiposity (BMI) in young adults (18-28 years) with childhood-onset obesity who have demonstrated low or medium treatment response to prior behavioral interventions.

For young adults with obesity who have not lost enough weight through standard diet and exercise programs, adding weekly semaglutide (2.4 mg) to their existing care plan is a clinically validated strategy to further reduce body mass index. The treatment involves a gradual dose increase over 16 weeks to minimize side effects, followed by 52 weeks of maintenance, all while continuing behavioral counseling.

Tirzepatide facilitates significant weight loss and improves lipid profiles in individuals with spinal cord injury (SCI) who are refractory to standard dietary and exercise interventions.

If you have a spinal cord injury and have tried strict diet and exercise without success, ask your doctor about tirzepatide. It is a weekly injection that helped this patient lose 33 pounds and improve his cholesterol, even when standard lifestyle changes failed. Be aware that GI side effects are possible, though this patient tolerated them well.

Consuming protein immediately before resistance training may increase lower body (leg press) strength gains more than consuming it immediately after.

If you are focusing on leg strength, try eating your protein 15 minutes before your workout. This might give you a slight edge in strength gains compared to drinking it after, possibly because it provides fuel for your legs. However, this finding is based on very limited data, so don't stress if you can't make it work.

Adding supportive accountability components (introductory video call, drop-in webchat, goal setting, food diary review) to a core digital behavioral weight loss program is hypothesized to enhance weight loss and engagement by increasing participant adherence through trust and accountability.

To get the most out of a digital weight loss program, look for one that offers flexible, on-demand access to a coach (like chat or video) and structured goal-setting. These features help keep you accountable without being overwhelming, which is key to sticking with the program long enough to lose weight.

Inpatient administration of GLP-1 receptor agonists (liraglutide and semaglutide) combined with a very low-calorie diet (800 kcal/day) produces rapid, substantial weight loss (25% of baseline) in severely obese patients (BMI > 100 kg/m2) who are hospitalized.

For severely obese patients (BMI > 100) who struggle with discharge or outpatient adherence, inpatient GLP-1RA therapy combined with a strict 800 kcal/day diet can produce rapid, substantial weight loss (approx. 25% in <8 months). This approach may serve as a bridge to bariatric surgery or functional independence when standard outpatient care fails due to socioeconomic or medical barriers.